Carole Inglevert

This whitepaper provides an overview of the technology transfer process and describes the development and optimization of a platform to manufacture a vaccine for tropical diseases.

This collection of insights, produced through a partnership between

, and Bioprocess Online, highlights strategies and guidance to ensure reliable biomanufacturing capacity and supply chains for the delivery of health technologies like vaccines, even during crisis conditions.

Purification efficiency evaluated endotoxin and host cell protein (HCP) clearance, plasmid yield, potential interference of the detergents with analytical in-process control assays, and overall process compatibility, and this comprehensive screening approach provides valuable insights to intensified plasmids production.

The covid-19 pandemic forced rapid vaccine development and market approval, shortening a process that normally takes years to just a few months. This experience raises a tantalising question: can such speed be sustained for other treatments?

Check out this article where

‘s Eva Schaefer, Director of Supply Robustness, and Tom Elich, MSAT Manager, discuss how industry collaboration has never been more important.

Vaccine Development collaboration: from Schistosomiasis to COVID-19 vaccine.

A wide range of novel vaccine modalities and conventional approaches are used to prevent and reduce the impact of infection. Adoption of templated manufacturing processes tailored to the specific modality can optimize and accelerate production workflows.

In this On-Demand version of the presentations, key opinion leaders from

, Hileman Laboratories Singapore, Baylor College of Medicine or Biofarma, provide a fascinating story of the behind of the scenes development of the recent pandemic and how long-term collaboration to optimize a neglected tropical disease vaccine platform transformed into the COVID-19 vaccine candidates.

mRNA technology has proven to enable rapid drug development. mRNA is an attractive modality to work with because of its relative simplicity compared to other biologics; it is wholly synthetic and does not require cellular materials.

Get a step-by-step overview of the plasmid DNA manufacturing process and the challenges in pDNA downstream purification, for mRNA, plasmid-based DNA Vaccines, and Viral Vector applications.